Print

Purpose

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

Condition

Eligibility

Eligible Ages
Over 12 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab OR - patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria

Exclusion Criteria

  • Hospitalized due to COVID-19 (excludes nosocomial infection) - Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19

Study Design

Phase
Study Type
Expanded Access

Recruiting Locations

Site
Palo Alto, California 94304

Site
Boston, Massachusetts 02114

Site
St Louis, Missouri 63110

Site
Seattle, Washington 98109

More Details

NCT ID
NCT05235347
Status
No longer available
Sponsor
Vir Biotechnology, Inc.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.